David Wu

List of Publications by Citations

52 papers	1,914 citations	18 h-index	43 g-index
55 ext. papers	2,441 ext. citations	4.4 avg, IF	4.41 L-index

#	Paper	IF	Citations
52	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. *Blood*, **2016**, 127, 2406-10	2.2	436
51	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. *Blood*, **2017**, 129, 1646-1657	2.2	234
50	Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. *Journal of Molecular Diagnostics*, **2014**, 16, 56-67	5.1	203
49	High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. *Science Translational Medicine*, **2012**, 4, 134ra63	17.5	175
48	Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. *Clinical Cancer Research*, **2014**, 20, 4540-8	12.9	110
47	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. *Blood*, **2018**, 131, 1350-1359	2.2	108
46	Mass cytometry of Hodgkin lymphoma reveals a CD4 regulatory T-cell-rich and exhausted T-effector microenvironment. *Blood*, **2018**, 132, 825-836	2.2	85
45	ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. *Blood Advances*, **2019**, 3, 2962-2979	7.8	55
44	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. *American Journal of Surgical Pathology*, **2018**, 42, 293-305	6.7	52
43	Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. *Modern Pathology*, **2014**, 27, 1438-46	9.8	45
42	Pathology of Castleman Disease. *Hematology/Oncology Clinics of North America*, **2018**, 32, 37-52	3.1	45
41	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. *Blood Advances*, **2019**, 3, 4065-4080	7.8	38
40	CADD score has limited clinical validity for the identification of pathogenic variants in noncoding regions in a hereditary cancer panel. *Genetics in Medicine*, **2016**, 18, 1269-1275	8.1	30
39	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 380-385	4.7	28
38	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. *Blood Advances*, **2020**, 4, 6039-6050	7.8	24
37	Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma. *Genes Chromosomes and Cancer*, **2016**, 55, 278-87	5	22
36	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1615-1620	4.7	20

35	Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes. *Haematologica*, **2017**, 102, 1549-1557	6.6	19
34	A novel disease-causing synonymous exonic mutation in affecting RNA splicing. *Blood*, **2018**, 132, 1211-1215	17.1	17
33	Flow cytometry for non-Hodgkin and classical Hodgkin lymphoma. *Methods in Molecular Biology*, **2013**, 971, 27-47	1.4	17
32	How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for variant curation for germline predisposition to myeloid malignancies. *Haematologica*, **2020**, 105, 870-887	6.6	14
31	Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. *Cytometry Part B - Clinical Cytometry*, **2014**,	3.4	14
30	Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1. *Cytometry Part B - Clinical Cytometry*, **2019**, 96, 67-72	3.4	14
29	Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. *Cytometry Part B - Clinical Cytometry*, **2015**, 88, 58-63	3.4	12
28	Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma. *Cytometry Part B - Clinical Cytometry*, **2016**, 90, 424-32	3.4	12
27	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. *American Journal of Hematology*, **2020**, 95, 1553-1561	7.1	9
26	Clinical Experience With Modified, Single-Tube T-Cell Receptor Vβ Flow Cytometry Analysis for T-Cell Clonality. *American Journal of Clinical Pathology*, **2016**, 145, 467-85	1.9	9
25	Cross-Platform DNA Encoding for Single-Cell Imaging of Gene Expression. *Angewandte Chemie - International Edition*, **2016**, 55, 8975-8	16.4	8
24	Full-Length Isoforms of Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Accumulate in the Cytoplasm of Cells Undergoing the Lytic Cycle of Replication. *Journal of Virology*, **2017**, 91,	6.6	7
23	Jumping translocations in myelodysplastic syndromes. *Cancer Genetics*, **2016**, 209, 395-402	2.3	7
22	Cutaneous T-cell lymphoma in sub-Saharan Africa. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 275-280	7.3	6
21	Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. *British Journal of Haematology*, **2018**, 183, 601-607	4.5	6
20	Flow cytometric features of incidental indolent T lymphoblastic proliferations. *Cytometry Part B - Clinical Cytometry*, **2020**, 98, 282-287	3.4	5
19	Myeloid/lymphoid neoplasms with FLT3 rearrangement. *Modern Pathology*, **2021**, 34, 1673-1685	9.8	5
18	Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia. *Pediatric Blood and Cancer*, **2016**, 63, 1667-70	3	5

17	Computer-aided detection of rare tumor populations in flow cytometry: an example with classic Hodgkin lymphoma. *American Journal of Clinical Pathology*, **2015**, 144, 517-24	1.9	3
16	Targeted Next-Generation Sequencing of Acute Leukemia. *Methods in Molecular Biology*, **2017**, 1633, 163-184	1.4	3
15	Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas. *Methods in Molecular Biology*, **2019**, 1956, 35-60	1.4	3
14	Ultrasensitive Detection of Chimerism by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing of Copy Number Deletion Polymorphisms. *Clinical Chemistry*, **2018**, 64, 938-949	5.5	2
13	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. *Blood*, **2016**, 128, 1086-1086	2.2	2
12	Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH. *Blood*, **2013**, 122, 2550-2550	2.2	1
11	Comprehensive Evaluation and Validation of a Next-Generation Sequencing Assay for Minimal Residual Disease Detection in T-Lymphoblastic Leukemia/Lymphoma. *Blood*, **2019**, 134, 1475-1475	2.2	1
10	De Novo Identification and Visualization of Important Cell Populations for Classic Hodgkin Lymphoma Using Flow Cytometry and Machine Learning. *American Journal of Clinical Pathology*, **2021**, 156, 1092-1102	1.9	1
9	A Curriculum for Genomic Education of Molecular Genetic Pathology Fellows: A Report of the Association for Molecular Pathology Training and Education Committee. *Journal of Molecular Diagnostics*, **2021**, 23, 1218-1240	5.1	1
8	Commentary on A Case of Rapid Deterioration with Marked Hypergammaglobulinemia. *Clinical Chemistry*, **2020**, 66, 1379-1380	5.5	
7	Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT). *Blood*, **2020**, 136, 23-23	2.2	
6	Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade. *Blood*, **2019**, 134, 1493-1493	2.2	
5	Bone Marrow Involvement Detected By Multi-Parameter Flow Cytometry Predicts Poor Outcome after Autologous Stem Cell Transplantation for Peripheral T-Cell Lymphoma. *Blood*, **2015**, 126, 1972-1972	2.2	
4	Detection of Mutations in Inherited Bone Marrow Failure and Myelodysplastic Syndrome Genes Using Genomic Capture and Massively Parallel Sequencing in Clinical Diagnostics. *Blood*, **2016**, 128, 1507-1507	2.2	
3	On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing. *Blood*, **2013**, 122, 1341-1341	2.2	
2	Detection Of Recurrent/Persistent Disease By T-Cell Receptor Repertoire Profiling In Patients With Mature T-Cell Neoplasm. *Blood*, **2013**, 122, 2614-2614	2.2	
1	Cross-Platform DNA Encoding for Single-Cell Imaging of Gene Expression. *Angewandte Chemie*, **2016**, 128, 9121-9124	3.6	